23andMe will file a Form 25 Notification of Delisting with the SEC around June 6, removing its stock from the Nasdaq.
The company's stock trading was initially suspended on March 31, 2025, and Nasdaq was expected to file Form 25.
Regeneron Pharmaceuticals is acquiring 23andMe's assets for $256 million, pending court approval and expected to close in Q3 2025.
23andMe achieved a peak valuation of approximately $6 billion after going public via a SPAC merger in 2021 but struggled with recurring revenue.
23andMe, once a prominent player in at-home DNA testing, gained popularity for allowing customers to explore their genetic profiles. However, after its public debut through a special purpose acquisition company (SPAC) merger in 2021, the company faced challenges in generating consistent revenue and establishing sustainable research or therapeutics businesses.
The decision to delist from the Nasdaq and deregister with the SEC marks a significant turning point for 23andMe. Regeneron Pharmaceuticals' acquisition provides a lifeline for the company's assets, pending approval from the U.S. Bankruptcy Court for the Eastern District of Missouri. This acquisition is anticipated to finalize in the third quarter of this year.
The company's struggles highlight the difficulties faced by businesses that gained initial traction but failed to maintain sustainable growth and profitability in the long term.
Q: Why is 23andMe delisting from Nasdaq?
23andMe is voluntarily delisting after filing for Chapter 11 bankruptcy and agreeing to be acquired by Regeneron Pharmaceuticals.
Q: When will the delisting take effect?
23andMe will file a Form 25 around June 6, 2025, to remove its securities from Nasdaq.
23andMe's delisting reflects challenges in maintaining growth after going public.
Regeneron's acquisition offers a new direction for 23andMe's assets.
The at-home DNA testing market faces hurdles in achieving long-term sustainability.
Investors should be aware of the risks associated with SPAC mergers and emerging technology companies.
What do you think about the future of personalized genetic testing? Share your thoughts in the comments below!
Share this article with others who need to stay ahead of this trend!
The highly anticipated public debut of Elon Musk's SpaceX, set for Friday, June 11, 2026, marks a potential watershed moment for capital mar...
As SpaceX prepares for what could be the largest Initial Public Offering (IPO) in history, understanding the terminology and processes invo...
United Rentals (URI) is experiencing a surge in market confidence and expanding its reach through strategic partnerships. The company's stoc...
Two mortgage brokers, Duane Buziak Mortgage Maestro and Bridgepoint Funding, are celebrating significant milestones in their careers, highli...
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer